Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1995-06-07
2000-09-05
Woodward, Michael P.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
424 931, 424 936, 4352351, 4352361, 435237, 4351723, 4353201, H61K 3929, C12N 700, C12N 701
Patent
active
061139122
ABSTRACT:
A live hepatitis A virus adapted to growth in MRC-5 cells, which HAV is preferably characterized by suitable attenuation for effective vaccine administration to humans and animals without inactivation, methods for adapting HAV to growth in MRC-5, vaccine compositions and method of vaccinating humans against HAV infection.
REFERENCES:
patent: 4532215 (1985-07-01), Daemer et al.
patent: 4620978 (1986-11-01), Daemer et al.
patent: 4636469 (1987-01-01), Daemer et al.
patent: 4783407 (1988-11-01), Provost et al.
patent: 4894228 (1990-01-01), Purcell et al.
Emerson et al., J. Virol. 66(2):650-654, Feb. 1992.
Provost et al. J. Med. Virol. 34(4):227-231, 1991.
Fineschi et al. J. Hepatol. 13(4):S146-S151, Apr. 1991.
Karron et al. J. Infect. Dis. 157(2):338-345, Feb. 1988.
Day et al., "A Single Base Mutation in the 5' Noncoding Region of HAV Enhances Replication of Virus In Vitro", Vaccines 90. Modern Approaches to New Vaccines Including Prevention of Aids, pp. 175-178 (1990).
Ross et al., "Molecular Cloning of cDNA From Hepatitis A Virus Strain HM-175 After Multiple Passages In Vivo and In Vitro", J. Med. Virol., vol. 67, pp. 1741-1744 (1986).
Najarian et al., "Primary Structure and Gene Organization Of Human Hepatitis A Virus", Proc. Nat'l. Acad. Sci. USA, vol. 82 pp. 2627-2631 (1985).
B. Ross et al, "Nucleotide Sequence of High-Passage Hepatitis A Virus Strain HM175: Comparison with Wild-type and Cell Culture-adapted Strains", J. Gen. Virol., 70:2805-2810 (Oct., 1989).
R. Jansen et al, "Complete Nucleotide Sequence of a Cell Culture-Adapted Variant of Hepatitis A Virus: Comparison with Wild-Type Virus with Restricted Capacity for in Vitro Replication", Virol., 163:299-307 (1988).
V. Tedeschi et al, "Partial Characterzation of Hepatitis A Viruses from Three Intermediate Passage Levels of a Series Resulting in Adaptation to Growth in Cell Culture and Attenuation of Virulence", J. Med., Virol., 39(1):16-21 (Jan. 1993).
N. Fineschi et al, "Characterization of a Hepatitis A Virus Strain Suitable for Vaccine Production", J. Hepatol., 13(4):S146-S151 (Apr., 1991).
P. Provost et al, "New Findings in Live, Attenuated Hepatitis A Vaccine Development", J. Med. Virol., 20:165-175 (1986) [Provost].
K. Midthun et al, "Safety and Immunogenicity of a Live Attenuated Hepatitis A Virus Vaccine in Seronegative Volunteers", J. Infect. Dis., 163:735-739 (Apr., 1991).
J. Mao et al, "Primary Study of Attenuated Live Hepatitis A Vaccine (H2 Strain) in Humans", J. Infect. Dis., 159(4):621-624 (Apr., 1989).
I. Gust et al, "The Origin of the HM175 Strain of Hepatitis A Virus", J. Infect. Dis., 151(2):365-366 (Feb., 1985).
F. Andre et al, "Inactivated Candidate Vaccines for Hepatitis A", Prog. Med. Virol. Basel, Karger, 37:72-95 (1990).
R. Daemer et al, "Propagation of Human Hepatitis A Virus in African Green Monkey Kidney Cell Culture: Primary Isolation and Serial Passage", Infect. Immun., 32:388-393 (Apr., 1981).
J. Melnick, "New Picornavirus Vaccines for Hepatitis A, and Lessons from the Control of Poliomyelitis by the Prototype Picornavirus Vaccines", Prog. Med. Virol. Basel, Karger, 37:47-55 (1990).
R. Karron et al, "Studies of Prototype Live Hepatitis A Virus Vaccines in Primate Models", J. Infect. Dis., 157(2):338-345 (Feb., 1988).
S. Emerson et al, "Mutations Responsible for Adaptation of Hepatitis A Virus to Efficient Growth in Cell Culture", J. Virol., 65(9):4882-4886 (Sep., 1991).
J. Cohen et al, "Complete Nucleotide Sequence of Wild-Type Hepatitis A Virus: Comparison with Different Strains of Hepatitis A Virus and Other Picornaviruses", J. Virol., 61(1):50-59 (Jan., 1987) [Cohen I].
J. Cohen et al, "Complete Nucleotide Sequence of an Attenuated Hepatitis A Virus: Comparison with Wild-Type Virus", Proc. Natl. Acad. Sci. USA, 84(8):2497-2501 (Apr., 1987) [Cohen II].
S. Lemon et al, "Serum Neutralizing Antibody Response to Hepatitis A Virus", J. Infect. Dis., 148(6):1033-1039 (Dec., 1983).
R. Purcelle et al, "A Microtiter Solid-Phase Radioimmunoassay for Hepatitis A Antigen and Antibody", J. Immunol., 116(2):349-356 (Feb., 1976).
J. Ticehurst et al, "Detection of Hepatitis A Virus by Extraction of Viral RNA and Molecular Hybridization", J. Clin. Microbiol., 25(10):1822-1829 (Oct., 1987).
J. Cohen et al, "Hepatitis A Virus cDNA and its RNA Transcripts are Infectious in Cell Culture", J. Virol., 61(10):3035-3039 (Oct., 1987) [Cohen III].
P. Provost et al, "Further Evaluation of a Live Hepatitis A Vaccine in Marmosets", J. Med. Virol., 34(4):227-231 (Aug., 1991) [Provost II].
B. Robertson et al, "Genetic Relatedness of Hepatitis A Virus Strains Recovered from Different Geographical Regions", J. Gen. Virol., 73:1365-1377 (May, 1992).
J. Graff et al, "Nucleotide Sequence of Wild-Type Hepatitis A Virus GBM in Comparison with Two Cell Culture-Adapted Variants", J. Virol., 68(1):548-554 (Jan., 1994).
F. Andre, "Approaches to a Vaccine Against Hepatitis A: Development and Manufacture of an Inactivated Vaccine", J. Infect. Dis., 171(Suppl 1):S33-S39 (Mar., 1995).
J. Peetermans, "Production, Quality Control and Characterization of an Inactivated Hepatitis A Vaccine", Vaccine, 10(Suppl 1):S99-S101 (Nov., 1992).
F. Andre, "Hepatitis A in Travellers: Development of a Safe, Immunogenic and Efficacious Inactivated Vaccine", Travel Medicine International, 13(1):10-14 (Jan., 1995).
Product Insert, "HA:L3A Prescribing Information, Hepatitis A Vaccine, Inactivated Havrix", distributed by SmithKline Beecham Pharmaceuticals (Feb., 1995).
Emerson et al., J. Virol., 66(2):650-654, Feb. 1992.
Provost et al., J. Med. Virol., 34(4):227-231, 1991 (Ref. B.S.).
Kineschi et al., J. Hepatol., 13(4):S146-S151, Apr. 1991 (Ref A.U.).
Karron et al., J. Infect. Dis., 157(2):338-345, Feb. 1988, (Ref. AAT).
D'Hondt Eric
Emerson Suzanne U.
Funkhouser Ann W.
Purcell Robert H.
The United States of America as represented by the Department of
Woodward Michael P.
Zeman Mary K
LandOfFree
Hepatitis A virus vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepatitis A virus vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis A virus vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2209261